Health Plans For State Employees Use Medicare’s Hammer On Hospital Bills

NPR, March 20, 2019
by Julie Appleby

States. They're just as perplexed as the rest of us over the ever-rising cost of health care premiums. Now some states –including Montana, North Carolina and Oregon — are moving… Read More

Ending HIV In Mississippi Means Cutting Through Racism, Poverty And Homophobia

NPR, March 16, 2019
by Ari Shapiro and Dave Blanchard

Ending HIV transmission in America within the next decade — a stated goal of the Trump Administration — isn't a question of coming up with new medication. The medicines to prevent… Read More

The Challenges of Innovating Access to Abortion

New Yorker, March 6, 2019
by Sue Halpern

[...] Telemedicine—obtaining medical services over the phone or through the Internet—is not a new phenomenon. In the U.S., it began to take off in the late nineteen-fifties, and a 2016… Read More

Pharmaceutical Company CEOs Face Grilling In Senate Over High Drug Prices

NPR, February 26, 2019
by Alison Kodjak

The leaders of seven drug industry giants were forced to defend their industry's prices and business practices on Capitol Hill on Tuesday, as lawmakers criticized them for failing to put patients before… Read More

Pharma’s day in Congress

BioPharma Dive, February 26, 2019
by Ned Pagliarulo and Andrew Dunn, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Criticism from several Republican senators was notable, namely in how similar the conservatives sounded to their Democratic counterparts. Lawmakers on both sides of the aisle were "advancing… Read More

American Travelers Seek Cheaper Prescription Drugs In Mexico And Beyond

NPR, February 11, 2019
by Bram Sable-Smith

[...] The U.S. government estimates that close to 1 million people in California alone cross to Mexico annually for health care, including to buy prescription drugs. And between 150,000 and 320,000… Read More

Trump Highlights Health Agenda With Vow To Lower ‘Unfair’ Drug Prices

Kaiser Health News, February 6, 2019
by Julie Rovner

It was not the centerpiece, but health was a persistent theme in President Donald Trump’s State of the Union address at the Capitol on Tuesday night. Although the administration has focused more… Read More

Petrie-Flom Center Seeks RA for Project on Drug Pricing

Petrie-Flom Center, Applications due January 25!

Call for Applications: Research Assistant, Drug Pricing in the U.S. and GloballyThe Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School seeks a Research Assistant… Read More

Call for Applications: Research Assistant, Drug Pricing in the U.S. and Globally
Petrie-Flom Center, Harvard Law School

Deadline: January 25, 2019

Description:The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School seeks a current Harvard graduate student to serve as Research Assistant in support of the… Read More

Health Care Industry Spends $30B A Year Pushing Its Wares, From Drugs To Stem Cell Treatment

Kaiser Health News, January 8, 2019
by Liz Szabo

Hoping to earn its share of the $3.5 trillion health care market, the medical industry is pouring more money than ever into advertising its products — from high-priced prescriptions to… Read More

Prescription Drug Costs Driven By Manufacturer Price Hikes, Not Innovation

NPR, January 7, 2019
by Alison Kodjak

The skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently… Read More

AVAILABLE FOR PRE-ORDER! Transparency in Health and Health Care in the United States

Cambridge University Press, Forthcoming June 2019
by Holly Fernandez Lynch, I. Glenn Cohen, Carmel Shachar, and Barbara J. Evans (eds.)

This edited volume stems from the Petrie-Flom Center’s 2017 annual conference, which brought together leading experts to reach better understandings of this health policy buzzword, recognizing… Read More

Limiting State Flexibility in Drug Pricing

NEJM, September 13, 2018
by Nicholas Bagley and Rachel E. Sachs (Academic Fellow Alumna)

From the article:  Throughout the United States, escalating drug prices are putting immense pressure on state budgets. Several states are looking for ways to push back. Last year, Massachusetts asked… Read More

Are Fraud and Abuse Laws Stifling Value-Based Care?

NEJM Catalyst , September 12, 2018
by Carmel Shachar (Executive Director)

From the article:  While health care delivery and financing should not be a free-for-all, designing the exemptions to explicitly conform to specific regulatory programs does not best serve the system.… Read More

Drug Pricing Policy

Health Affairs Blog, August 14, 2018
by Rachel E. Sachs (Academic Fellow Alumna)

From the post:  Last Tuesday, the Centers for Medicare and Medicaid Services (CMS) took its latest action in the area of drug pricing. CMS gave Medicare Advantage (MA) plans the ability… Read More

The Trump admin has another pretty good, pretty modest plan to lower drug costs

Vox, August 13, 2018
by Dylan Scott, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: “My concern is that once again, the administration’s rhetoric is out of step with its actual policy moves,” Sachs said. “The administration is promoting this move… Read More

Perspective: Will Courts Allow States to Regulate Drug Prices?

NEJM, August 8, 2018
by Christopher Robertson (Academic Fellow Alumnus)

From the article: Pharmaceuticals are consuming increasingly large portions of U.S. state budgets, and high prices are preventing patients from getting, and adhering to, essential medicines. In mid-May… Read More

Report blames gaming of patent system for high drug prices

Med City News, August 9, 2018
by Alaric Dearment, quoting W. Nicholson Price II (Academic Fellow Alumnus)

[...] The report, “Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices,” was released last week by the nonprofit Initiative… Read More

CMS’ plan to lower drug spending in Medicare Advantage

Politico Pulse, August 8, 2018
by Brianna Ehley, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Some viewed the step as a bit of a letdown, since HHS Secretary Alex Azar has been touting more sweeping changes to drug prices in Medicare Part B, like letting the private sector insurance… Read More

To Tame Prescription Prices, HHS Dips A Toe Into Drug Importation Stream

Kaiser Health News, August 1, 2018
by Rachel Bluth, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: This isn’t the first time officials have suggested importing drugs from other countries to find better prices. Bills have been offered in Congress to allow it, and George… Read More

On the Human Right to Health

Human Rights, Democracy, and Legitimacy in a World of Disorder , 2018
by I. Glenn Cohen (Faculty Director)

Faculty Director I. Glenn Cohen has written a chapter in the fortchoming book "Human Rights, Democracy, and Legitimacy in a World of Disorder," (Cambridge University Press, edited by Silja… Read More

Medical Tourism: Once Ready for Takeoff, Now Stuck at the Gate

Managed Care, March 28, 2018
by Richard Mark Kirkner, quoting I. Glenn Cohen (Faculty Director)

From the article: Consultants predicted it would be a major business. Large employers and insurers were experimenting with it. But medical tourism has not lived up to the heady expectations. The ACA and… Read More